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Abstract: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the US 
Food and Drug Administration for the treatment of fibromyalgia and painful diabetic neuropa-
thy at doses of 60 mg daily. Duloxetine has been shown to significantly improve the symptoms 
of chronic pain associated with these disorders, as measured by the Fibromyalgia Impact 
  Questionnaire, Brief Pain Inventory scores, the Clinical Global Impressions Scale, and other 
various outcome measures in several placebo-controlled, randomized, double-blind, multicenter 
studies. Symptom improvement generally began within the first few weeks, and continued for the 
duration of the study. In addition, the efficacy of duloxetine was found to be due to direct effects 
on pain symptoms rather than secondary to improvements in depression or anxiety. Adverse 
events including nausea, constipation, dry mouth, and insomnia, were mild and transient and 
occurred at relatively low rates. In conclusion, duloxetine, a selective inhibitor for the serotonin 
and norepinephrine transporters, is efficacious in the treatment of chronic pain associated with 
fibromyalgia or diabetic neuropathy, and has a predictable tolerability profile, with adverse 
events generally being mild to moderate.
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Introduction
Chronic pain is a serious and debilitating condition with a large financial burden to 
the suffering individual, their family, and society. The etiology of chronic pain can be 
due to a multitude of factors, from malignant disease to diabetic neuropathy. Whatever 
the cause, chronic pain is highly stressful for the patient, and can lead to additional psy-
chiatric and somatic conditions (Table 1).1 Treatment of chronic pain using established 
interventions remains difficult and therefore further options are necessary. In addition 
to treating pain directly using pharmacologic and nonpharmacologic interventions, it 
is also important to treat comorbid conditions, such as major depressive disorder and 
anxiety, both of which are found to be strongly associated with chronic pain disorders.2 
Chronic pain due to nonmalignant causes is believed to affect 9% of adults in the US,3 
and approximately 20% of the world’s population.4
Two types of nonmalignant chronic pain disorders are fibromyalgia and neuropathic 
pain. Neuropathic pain is reported by approximately 3% of the population at some time 
during their lives,5 and is characterized by tingling, burning, shock-like or shooting 
sensations, allodynia, and hyperalgesia.6,7 There are a number of disorders associated 
with neuropathic pain, the most common being diabetic neuropathy and lower back 
pain. Others include human immunodeficiency-associated pain, phantom pain, and 
multiple sclerosis.6–8 The pathophysiology of neuropathic pain is complex and numerous Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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mechanisms may be involved.9 Perhaps due to the multiple 
etiologies of neuropathic pain, many types of drug classes are 
used in its treatment. Current recommendations for first-line 
therapy involve the use of tricyclic antidepressants, serotonin-
norepinephrine reuptake inhibitors, antiepileptic drugs, and 
topical anesthetics. Second-line options involve the use of 
opioids and tramadol.8,10 Nonpharmacologic interventions are 
also used to treat neuropathies, and include techniques such 
as spinal cord stimulation,11 acupuncture,12 and psychologic 
interventions.13
Fibromyalgia is an idiopathic, chronic, nonarticular pain 
syndrome, and is defined by The American College of Rheu-
matology as widespread pain in combination with tenderness 
at 11 of 18 specific tender point sites, with at least a three-
month duration.14 Patients will describe the pain as burning 
or gnawing, and also complain of stiffness.15 In addition to 
the musculoskeletal pain symptoms, patients often suffer 
from headaches, fatigue, mood and anxiety disorders, sleep 
disturbances, and cognitive disturbances.15,16 It is believed 
that approximately 0.5%–5.0% of the population suffers 
from fibromyalgia.17,18 Risk factors associated with a higher 
prevalence of fibromyalgia include female gender, increasing 
age, and belonging to a lower socioeconomic group.18
The pathophysiology of fibromyalgia is not fully 
understood, but compounds that increase serotonin and 
norepinephrine activity have proven efficacious in treat-
ing fibromyalgia.19 Duloxetine, a serotonin-norepinephrine 
reuptake inhibitor, is approved by the US Food and Drug 
Administration (FDA) for the treatment of painful diabetic 
neuropathy and fibromyalgia. This article will review the 
efficacy of duloxetine in the treatment of both of these chronic 
pain disorders.
Duloxetine
Pharmacodynamics
Duloxetine is a selective serotonin and norepineph-
rine reuptake inhibitor that is approved by the FDA for 
major depressive disorder, generalized anxiety disorder, 
  diabetic peripheral neuropathic pain, and fibromyalgia.20 
Its   mechanism of action is through the blockade of reuptake 
of serotonin (5-HT) and norepinephrine. Studies show that 
duloxetine inhibits 5-HT and norepinephrine uptake in 
the hypothalamic synaptosomes of rats with a preference 
for 5-HT.21
Platelet serotonin measurements can be used to show 
5-HT reuptake inhibition due to the 5-HT reuptake func-
tion of platelets. An increase in whole blood 5-HT content 
represents 5-HT reuptake inhibition. Studies have shown 
a dose-dependent increase in whole blood 5-HT levels in 
patients taking duloxetine.22 Studies using positron emission 
tomography also indicate duloxetine’s ability to inhibit 5-HT 
reuptake. One such study demonstrated serotonin transporter 
(5-HTT) occupancy in subjects dosed with duloxetine, 
thus establishing duloxetine’s ability to block the reuptake 
of 5-HT.23
Several methods have been utilized to demonstrate nor-
epinephrine reuptake inhibition by duloxetine. These include 
changes in urinary excretion of norepinephrine and metabo-
lites, changes in cardiovascular effects, and monitoring of 
adverse event profiles.24 A decrease in whole body norepi-
nephrine (norepinephrine plus its metabolites) in urinary 
excretion indicates decreased norepinephrine reuptake. 
Chalon et al demonstrated that there was a decrease in 
urinary excretion of norepinephrine metabolites, and not 
norepinephrine itself, in duloxetine treatment groups.25 An 
increase in supine systolic blood pressure is also indicative 
of blocked norepinephrine reuptake. This was demonstrated 
in patients taking duloxetine 80 mg/day.25
Pharmacokinetics
Oral duloxetine hydrochloride is well absorbed, with a time 
to peak plasma concentration of six hours.20 Food does not 
change the peak concentration, but will delay Tmax to up 
to 10 hours and slightly decreases total absorption.20 The 
steady state of duloxetine is reached in three days, indepen-
dent of dose, with a mean terminal elimination half-life of 
12.5 hours.26 Duloxetine pharmacokinetics are linear with 
respect to dose.27 The mean oral clearance based on the aver-
age of eight subjects was 114 L/hour, and apparent volume of 
distribution was 1943 L.27 Duloxetine is 90% protein-bound,20 
therefore caution should be exercised when administering 
duloxetine concomitantly with medications that are highly 
protein-bound, such as warfarin and phenytoin.
Duloxetine metabolism and elimination is mainly 
through the liver, involving cytochrome (CYP)1A2 and 
CYP2D6 isoenzymes,20 and has an extensive biotransfor-
mation through oxidation, methylation, and/or conjugation 
Table 1 Somatic and psychological manifestations of pain1
Physical attributes Psychologic attributes
Hypertension Anxiety
Tachycardia Depression
Diaphoresis Fear
Mydriasis Anger
Pallor insomnia
Gastrointestinal distressJournal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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  pathways.27 In a study using four subjects, urine collection 
was performed for 72 hours after duloxetine ingestion, and 
using high-pressure liquid chromatography/radiochemical 
detection, researchers found approximately 94% of the 
radioactivity excreted in the urine as the various dulox-
etine metabolites. The major plasma metabolite is the 
glucuronide conjugate of 4-hydroxy duloxetine. Unchanged 
duloxetine was undetectable in the urine.27
Drug-drug interactions
Duloxetine is metabolized by CYP1A2 and CYP2D6 to 
form the various metabolites excreted mainly in the urine.28 
While duloxetine is a CYP2D6 substrate, it also is a moder-
ately potent inhibitor of CYP2D6 and insignificant inhibitor 
of CYP1A2.20,28 Due to duloxetine’s CYP2D6 inhibitory 
effect, care should be taken when coadministering other 
medications metabolized through this pathway. Furthermore, 
giving duloxetine with potent inhibitors of CYP2D6 and 
CYP1A2 should also be cautioned due to increases in dulox-
etine concentration.28 Several studies were done to examine 
the drug-drug interaction between duloxetine and CYP1A2 
and CYP2D6 inhibitors and inducers. In two studies using 
extensive genotypic CYP2D6 metabolizers, subjects were 
given duloxetine with either desipramine (a CYP2D6 sub-
strate), or paroxetine (a potent CYP2D6 inhibitor).29 In the 
duloxetine–desipramine study, concentrations of desipramine 
increased in the presence of duloxetine. In the duloxetine–
paroxetine study, duloxetine plasma concentrations increased 
moderately in the presence of paroxetine. Another potential 
drug interaction involves the use of anticoagulants (due to 
duloxetine’s small 1A2 inhibition).25 Pharmacodynamic drug 
interactions may also occur with monoamine oxidase inhibi-
tors and other serotonergic drugs, resulting in an increased 
risk of serotonin syndrome. An example of this involves an 
interaction between duloxetine and linezolid. Linezolid has 
been shown to be a nonselective inhibitor of monoamine 
oxidase.30 It is recommended that patients be monitored 
closely if taking duloxetine concomitantly with any of these 
drug classes.20
Efficacy in chronic pain
A Medline search was done using the keywords   “duloxetine”, 
“Cymbalta®”,  “chronic  pain”,  “neuropathic  pain”, 
  “fibromyalgia”, “efficacy”, and “controlled trial”. In addition, 
reference lists of relevant articles were thoroughly reviewed 
to determine additional sources of nonindexed published 
data. Randomized, double-blind, placebo-controlled trials 
of duloxetine for the treatment of either fibromyalgia or 
diabetic neuropathy were included for review. Eight Phase III 
controlled trials were found, five of which looked at the use 
of duloxetine in patients with fibromyalgia, and three looked 
at the use of duloxetine in patients with neuropathic pain. It 
is noteworthy that all data were based on industry-sponsored 
studies. The following section will summarize these trials, 
with each disorder being dealt with separately.
Fibromyalgia
Arnold et al31 conducted a randomized, multicenter, double-
blind, placebo-controlled trial to study the efficacy and 
tolerability of duloxetine in patients with fibromyalgia with 
or without current major depressive disorder. Study subjects 
were recruited from 18 sites in the US. The study consisted 
of a one-week, placebo lead-in phase followed by a 12-week, 
double-blind treatment phase. Subjects underwent a forced 
dose-titration phase for the first two weeks of treatment 
beginning with duloxetine 20 mg daily, which was titrated 
upwards to a dose of 60 mg twice daily. Primary outcome 
measures were defined by the Fibromyalgia Impact Ques-
tionnaire (FIQ) pain item and total score, with secondary 
outcomes including the FIQ items for fatigue, morning tired-
ness, and stiffness, number of tender points, and tender point 
pain threshold, the Clinical Global Impression of Severity 
(CGI-S) scale, the Patient Global Impression of Improvement 
(PGI-I) scale, and the Brief Pain Inventory (BPI) short form. 
Additionally, other secondary objectives sought to determine 
if the effects of duloxetine 60 mg twice daily on the FIQ pain 
scores were dependent on whether or not the subject suffered 
from major depressive disorder, and also looked at overall 
quality of life. Regarding this, outcome measures were the 
Beck Depression Inventory-II scale, the Beck Anxiety Inven-
tory (BAI) scale, the Medical Outcomes Study Short Form 
36 (SF-36), the Quality of Life in Depression Scale, and the 
Sheehan Disability Scale.
A total of 207 subjects entered the treatment phase of the 
study, with 104 receiving active treatment and 103 receiving 
placebo. Both treatment arms reported a decrease in total 
FIQ score from baseline, with the duloxetine-treated group 
showing a significantly greater decrease in total FIQ score 
as compared with placebo at week 12 (mean ± standard error 
[SE] for duloxetine was −13.46 ± 1.82 versus −7.93 ± 1.73 
for placebo, P = 0.027). Differences in FIQ subscores for 
pain, fatigue, and morning tiredness between both treat-
ment groups were not significant at 12 weeks. However, 
the difference in FIQ subscore for stiffness between both 
groups was significant at week 12 (mean ± SE for duloxetine 
was −2.33 ± 0.30 versus −1.51 ± 0.29 for placebo, P = 0.048). Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Both treatment groups experienced a reduction from baseline 
in number of tender points, as well as a reduction in mean 
tender point pain threshold, and in each case, those changes 
were significantly larger for the duloxetine group versus 
placebo. Differences between the two treatment groups in 
response rates, as defined by a 50% reduction in FIQ pain 
score, were not significant (27.7% for duloxetine versus 
16.7% for placebo, P = 0.06). Most of the SF-36 subscores, 
the Quality of Life in Depression Scale, and the Sheehan 
Disability Scale showed significantly greater improvements 
for the duloxetine group as compared with the placebo group. 
Secondary outcome measures that did not show significantly 
greater improvements for the duloxetine group versus pla-
cebo were the Beck Depression Inventory-II total score, the 
BAI total score, and the SF-36 mental, emotional role limit, 
and social functioning subscores.
A second study conducted by Arnold et al was a ran-
domized, multicenter, double-blind, placebo-controlled trial 
which looked at the efficacy and tolerability of duloxetine in 
women with fibromyalgia with or without major depressive 
disorder.32 This study was conducted at 21 sites in the US, 
and consisted of a 12-week treatment phase whereby subjects 
were randomized to receive either duloxetine 60 mg daily, 
duloxetine 60 mg twice daily, or placebo. The primary out-
come measure was the BPI (short form) 24-hour average pain 
severity score. Secondary outcomes were similar to those 
used in the previous study, except that this study included 
the BPI items for worst and least pain in the prior 24 hours, 
the FIQ total score, and the 17-item Hamilton Depression 
Rating Scale. A response was defined as a greater than 30% 
reduction in the BPI 24-hour average pain severity score.
A total of 354 women were enrolled into the treatment 
phase of the study and were randomly assigned to receive 
one of the three treatments, such that 118 subjects received 
duloxetine 60 mg daily, 116 subjects received duloxetine 
60 mg twice daily, and 120 patients received placebo. A total 
of 138 (39%) patients withdrew from the study during the 
treatment phase, but the rate of withdrawal was not significant 
between the three treatment groups (P = 0.407). However, 
the withdrawal rate was significant for active treatment 
groups versus placebo when measuring withdrawal rate due 
to adverse events.
For the primary outcome measure, there was a statistically 
significant improvement for both active treatments versus 
placebo. This improvement began at week 1 and continued 
through week 12, with the change from baseline of BPI 
average scores at week 12 being −2.39 ± 0.22 for dulox-
etine 60 mg daily (P , 0.001), −2.40 ± 0.22 for duloxetine 
60 mg twice daily, and −1.16 ± 0.21 for placebo. There was 
no significant difference between the two active treatment 
groups with regard to primary outcome.
The duloxetine 60 mg daily group demonstrated sig-
nificant improvements from baseline in all secondary out-
come measures, with the exception of mean tender point 
pain threshold and number of tender points with low pain 
  threshold. Likewise, for the duloxetine 60 mg twice daily 
group, all secondary outcome measures showed significant 
improvements versus placebo, except for the Hamilton 
Depression Rating Scale. A response rate of 44% was 
observed for the duloxetine 60 mg daily group (P , 0.001 
versus placebo), 43% for the duloxetine 60 mg twice daily 
group (P , 0.001 versus placebo), and 19% for placebo.
Two studies examined the efficacy and safety of duloxetine 
in fibromyalgia patients with or without major depressive 
disorder over a six-month period. Chappell33 conducted a 
double-blind, placebo-controlled study whereby patients 
were randomized to receive duloxetine 60–120 mg daily or 
placebo. Outcome measures were similar to those in previous 
studies, with the coprimary outcome measures being change 
from baseline to endpoint in average pain item of the BPI at 
six months, plus improvements in the PGI-I from baseline to 
endpoint at six months. Patients’ duloxetine doses were titrated 
upwards to 120 mg if they had not had a $50% improvement 
in their BPI scores by week 13. A total of 330 subjects, of 
which over 90% were Caucasian females, were enrolled in the 
study, with 162 being randomized to active treatment group 
and 168 to placebo. Contrary to previous studies, there was 
no statistically significant difference in primary outcome 
between duloxetine-treated and placebo-treated subjects. For 
the coprimary outcome of change in average pain item of the 
BPI, there was a mean improvement of −1.62 ± 0.20 for the 
duloxetine-treated group, and −1.13 ± 0.19 for the placebo 
group (P = 0.053). For the coprimary outcome of mean change 
in PGI-I, there was an improvement of 3.43 ± 0.13 (SE) for 
the duloxetine group versus 3.72 ± (0.12) for placebo group 
(P = 0.073). Many of the secondary outcome measures in this 
study also did not show significant differences between treat-
ment groups, but there were significant differences between 
treatment groups in BPI least pain score and average inter-
ference, FIQ pain score, CGS-S, Multidimensional Fatigue 
Inventory (MFI) mental fatigue score, BDI-II total score, and 
AUC (area under the curve) of pain relief: (as derived from 
the BPI  average pain score).
The other six-month study reported by Russell et al,34 
had the same coprimary endpoints as the Chappell study. 
A total of 520 subjects were enrolled in the study, with Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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278 completing the full six months of treatment. Subjects 
were randomly assigned in a 1:2:2:2 ratio to duloxetine 
20 mg once daily, 60 mg once daily, 120 mg once daily, 
or placebo. Subjects randomized to 60 mg or 120 mg had 
their doses titrated upwards from an initial dose of 30 mg 
per day. The 20 mg dose was used to determine the low-
est effective dose of duloxetine. At three months, there 
were significant improvements in both coprimary outcome 
measures. The BPI average pain severity score saw an 
improvement of −1.99 ± 0.20 for the duloxetine 60 mg/day 
group, −2.31 ± 0.20 for the duloxetine 120 mg/day group, 
and −1.39 ± 0.20 for placebo. Changes for both the 60 mg 
and 120 mg duloxetine groups were significant versus pla-
cebo, but the change observed in the 20 mg/day duloxetine 
group (−1.92 ± 0.27) was not significant versus placebo. 
Improvements in PGI-I scores for all three active treatments 
showed statistical significance versus placebo (mean ± SE 
for duloxetine 20 mg was 2.85 ± 18.82, for duloxetine 60 mg 
was 3.04 ± 0.13, for duloxetine 120 mg was 2.89 ± 0.13, and 
for placebo was 3.39 ± 0.13). For the six-month endpoint, 
changes in BPI average pain severity score were significant 
for all active treatments versus placebo (−2.22 ± 0.28 for the 
duloxetine 20 mg group, −19.98 ± 0.21 for duloxetine 60 mg, 
−2.26 ± 0.21 for duloxetine 120 mg, and −1.43 ± 0.21 for 
placebo). There were also significant improvements versus 
placebo for the duloxetine 20 mg and 120 mg groups in PGI-I 
score, but not for the 60 mg group (2.79 ± 0.17 for duloxetine 
20 mg, 3.08 ± 0.13 duloxetine 60 mg; P . 0.05 versus 
placebo, 2.93 ± 0.13 for duloxetine 120 mg, and 3.37 ± 0.13 
for placebo). Similar to the six-month Chappell study, many 
of the secondary outcome measures did not reach statistical 
significance when comparing active treatments with pla-
cebo. The scores for CGI-S and MFI mental fatigue were 
the only secondary outcomes to reach significance versus 
placebo across all three active treatments. Interestingly, these 
outcomes were also statistically significant in the Chappell 
study. In addition to the scores for mental fatigue on the 
CGI-I and MFI, secondary outcomes that were significant 
versus placebo for the duloxetine 120 mg group included 
all subsets of the MFI (except for the MFI general fatigue 
score), the SF-36 mental component summary, the BPI aver-
age pain severity score with and without major depressive 
disorder, and the PGI-I with major depressive disorder. For 
the duloxetine 60 mg group, no further secondary outcomes 
reached significance, while for the duloxetine 20 mg group, 
changes in the EuroQol EQ-5D and PGI-I without major 
depressive disorder were statistically significant versus 
placebo.
A fifth study that examined the long-term (52-week) 
  efficacy and safety of duloxetine in patients with fibromy-
algia was reported by Chappell et al.35 This was a random-
ized, multicenter Phase III study conducted at 33 centers 
internationally, and consisted of an eight-week, open-label 
phase followed by a 52-week, double-blind phase. Its primary 
goal was to evaluate the safety and tolerability of long-term 
duloxetine use in patients with fibromyalgia, but efficacy 
measures were used as secondary outcomes. Efficacy mea-
sures included the BPI-Modified Short Form, FIQ total score, 
PGI-I and CGI-S scores, number of tender points with a low 
threshold, mean of the 18 tender points pain threshold, and 
the Sheehan Disability Scale global functional impairment 
score. A response was defined as a greater than 50% reduction 
in BPI average pain score from baseline to endpoint during 
the open-label period.
A total of 350 fibromyalgia patients were enrolled in the 
open-label phase and were treated with duloxetine 60 mg 
daily for eight weeks. Of the 350 subjects, 307 continued 
to the double-blind phase where they were randomized to 
receive either duloxetine 60 mg daily or duloxetine 120 mg 
daily for 52 weeks. In the initial open-label phase, 34.8% 
of patients responded to therapy, and all efficacy outcome 
measures showed a statistically significant improvement from 
baseline. At the end of the double-blind period, there were 
significant differences between both treatment groups in a 
number of the efficacy outcome measures. These included 
changes from baseline (defined as assessments taken at the 
end of the open-label phase) in the BPI interference scores 
for walking ability, sleep, enjoyment of life, and average 
interference, with the 60 mg group showing greater improve-
ments than the 120 mg group. The duloxetine 60 mg group 
also showed significant improvements from baseline versus 
the 120 mg group for the mean PGI-I score, FIQ total score, 
mean tender point threshold, number of tender points with 
low threshold, and the Sheehan Disability Scale global 
functional impairment total score. Persistence of effect of 
duloxetine in pain reduction was assessed in those patients 
who had achieved a response and had continued to be treated 
with duloxetine 60 mg daily (36 subjects). In this case, per-
sistence of effect was not demonstrated. Table 2 contains a 
summary of the above studies.
Neuropathic pain
Goldstein et al36 reported on a 12 week, multicenter, parallel-
group, double-blind, randomized, placebo-controlled study 
of duloxetine use in patients diagnosed with diabetic neu-
ropathy. Pain had to have been present for at least six months Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Efficacy of duloxetine in treating pain in fibromyalgia patients
Study duration Study
Arnold et al31 Arnold et al32 Russell et al34 Chappell33 Chappell et al35
3 months 6 months 6 months 12 months
Baseline demographics
Percentage female 89 100 94.8 93.3 95.7
Mean age (years) 49 49.6 51 50.5 49
Treatment group DLX 120 mg PBO DLX 60 mg DLX 120 mg PBO DLX 20 mg DLX 60 mg DLX 120 mg PBO DLX 20 mg DLX 60 mg DLX 120 mg PBO DLX 60/120 mg PBO DLX 60 mg DLX 120 mg
n 104 103 118 116 120 79 150 147 144 49 97 95 84 162 168 104 203
Outcome measure (change from baseline ± SE)
FiQ total score −13.46 (1.82) −7.93 (1.73) −16.72 (1.53) −16.81 (1.54) −8.35 (1.53) −14.60 (1.83)* −15.41 (1.40)* −14.50 (1.38)* −10.05 (1.42) −14.77 (1.88) −12.28 (1.44) −13.86 (1.41) −10.42 (1.46) −7.96 (1.35) −5.81 (1.29) −0.69 (1.82) 3.49 (1.34)*
Mean tender point 
pain threshold
0.29 (0.07) −0.04 (0.07) 0.22 (0.08) 0.39 (0.08) 0.06 (0.08) 0.51 (0.11) 0.52 (0.08) 0.42 (0.08) 0.33 (0.08) 0.54 (0.12) 0.52 (0.09) 0.54 (0.09) 0.42 (0.09) 0.40 (0.09) 0.18 (0.08) 0.58 (0.11) 0.32 (0.08)*
Brief pain inventory
  Average pain −1.83 (0.24) −0.94 (0.23) −2.39 (0.22) −2.40 (0.22) −1.16 (0.21) −1.92 (0.27) −1.99 (0.2)* −2.31 (0.20)* −1.39 (0.20) −2.22 (0.28)* −1.98 (0.21)* −2.26 (0.21)* −1.43 (0.21) −1.62 (0.20) −1.13 (0.19) −0.37 (0.26) −0.16 (0.19)
  Worst pain – – −2.53 (0.25) −2.37 (0.25) −1.35 (0.24) – – – – – – – – −1.75 (0.22) −1.25 (0.21) −0.53 (0.28) −0.18 (0.21)
  Least pain – – −1.77 (0.20) −1.76 (0.20) −0.58 (0.20) – – – – – – – – −1.22 (0.19) −0.73 (0.18) −0.12 (0.26) 0.21 (0.19)
CGi-S −0.72 (0.12) −0.39 (0.12) −0.84 (0.10) −0.84 (0.10) −0.44 (0.10) −0.96 (0.12) −1.06 (0.10)* −1.10 (0.09)* 0.70 (0.10) −0.97 (0.13)* −1.07 (0.10)* −1.14 (0.10)* −0.66 (0.10 −0.57 (0.09) −0.28 (0.08) −0.23 (0.11) −0.04 (0.08)
PGi-i 3.02 (0.17) 3.53 (0.17) 3.11 (1.77) 3.06 (1.73) 3.71 (1.5) 2.85 (0.17)* 3.04 (−0.13)* 2.89 (0.13)* 3.39 (0.13) 2.79 (0.17)* 3.08 (0.13) 2.93 (0.13)* 3.37 (0.13) 3.43 (0.13) 3.72 (0.12) 2.19 (0.15) 2.65 (0.11)*
Notes: *Results were statistically significant (P , 0.05) versus placebo.
Abbreviations: Se, standard error; DLX, duloxetine; PBO, placebo; FiQ, Fibromyalgia impact Questionnaire; CGi-i, Clinical Global impressions of Severity; PGi-i, 
Patient’s Global impressions of improvement.
prior to the onset of the study, and rate a score of at least 3 
on the Michigan Neuropathy Screening Instrument. Subjects 
were randomized in a 1:1:1:1 fashion to receive duloxetine 
20 mg daily, duloxetine 60 mg daily, duloxetine 120 mg 
daily (given as 60 mg twice daily), or placebo for 12 weeks. 
The primary outcome measure was the mean change from 
baseline to endpoint on the 24-hour Average Pain Severity 
score. Secondary outcome measures included the Average 
Daily Severity and Average Night Severity pain scores, 
Worst Pain Severity score, BPI interference and severity 
scores, CGI-S, PGI-I, SF-36, EuroQol EQ-5D, the Beck 
Depression Inventory-II (BDI-II), and the BAI.
A total of 457 subjects were enrolled in the study, the 
majority of whom had Type 2 diabetes mellitus (88.4%), 
and had been diagnosed with diabetic neuropathy for a 
mean duration of 3.7 years, of whom 344 subjects completed 
the study. The primary outcome measure of mean change 
from baseline in 24-hour Average Pain Severity Score was 
statistically significant for the duloxetine 60 mg and dulox-
etine 120 mg groups versus placebo (mean change ± SE for 
duloxetine 60 mg was −2.89 ± 0.22, for duloxetine 120 mg 
was −3.24 ± 0.23, and for placebo was −1.91 ± 0.22). A 50% 
reduction in 24-hour Average Pain Severity Score from 
baseline to endpoint was achieved by 41% in the duloxetine 
20 mg group, 49% in the 60 mg group, 52% in the 120 mg 
group, and 26% in the placebo group (P , 0.05 for all active 
treatments versus placebo). All secondary outcome measures 
met statistical significance for the duloxetine 120 mg group, 
with the exception of the Dynamic Allodynia Severity 
score and the BAI score. For the duloxetine 60 mg group, 
there were also significant improvements versus placebo in 
secondary outcome measures of pain (an exception to this 
was the Dynamic Allodynia Severity score), but many of 
the depression and anxiety outcome measures did not show 
significant improvement versus placebo. For the duloxetine 
20 mg group, two secondary outcomes (CGI-S score, and 
SF McGill total score) showed greater improvement versus 
placebo. Further analysis of the data gathered in this study 
demonstrated that pain reduction in the duloxetine 60 mg 
group was 94.8%, attributable to a direct effect of the drug on 
pain symptoms (as opposed to a 0.2% indirect effect through 
mood improvement, and a 5.1% indirect effect through 
improvement in anxiety). This was also reflected in the 
duloxetine 120 mg group, which showed that improvements 
in pain symptoms were 88.6% due to a direct effect, and 
11.4% due to indirect effects.
Another 12-week trial studying the use of duloxetine in 
treating neuropathic pain was reported on by Raskin et al.37 
The study design was similar to the Goldstein et al study, 
except that this study did not include a duloxetine 20 mg 
group. There were 348 patients enrolled in the study, with 
116 being randomized into each of the following treatment 
groups: duloxetine 60 mg daily, duloxetine 120 mg daily 
(60 mg twice daily), and placebo. The primary outcome 
measure was the change in weekly mean of the 24-hour pain 
scores. Secondary outcome measures were also very similar Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Efficacy of duloxetine in treating pain in fibromyalgia patients
Study duration Study
Arnold et al31 Arnold et al32 Russell et al34 Chappell33 Chappell et al35
3 months 6 months 6 months 12 months
Baseline demographics
Percentage female 89 100 94.8 93.3 95.7
Mean age (years) 49 49.6 51 50.5 49
Treatment group DLX 120 mg PBO DLX 60 mg DLX 120 mg PBO DLX 20 mg DLX 60 mg DLX 120 mg PBO DLX 20 mg DLX 60 mg DLX 120 mg PBO DLX 60/120 mg PBO DLX 60 mg DLX 120 mg
n 104 103 118 116 120 79 150 147 144 49 97 95 84 162 168 104 203
Outcome measure (change from baseline ± SE)
FiQ total score −13.46 (1.82) −7.93 (1.73) −16.72 (1.53) −16.81 (1.54) −8.35 (1.53) −14.60 (1.83)* −15.41 (1.40)* −14.50 (1.38)* −10.05 (1.42) −14.77 (1.88) −12.28 (1.44) −13.86 (1.41) −10.42 (1.46) −7.96 (1.35) −5.81 (1.29) −0.69 (1.82) 3.49 (1.34)*
Mean tender point 
pain threshold
0.29 (0.07) −0.04 (0.07) 0.22 (0.08) 0.39 (0.08) 0.06 (0.08) 0.51 (0.11) 0.52 (0.08) 0.42 (0.08) 0.33 (0.08) 0.54 (0.12) 0.52 (0.09) 0.54 (0.09) 0.42 (0.09) 0.40 (0.09) 0.18 (0.08) 0.58 (0.11) 0.32 (0.08)*
Brief pain inventory
  Average pain −1.83 (0.24) −0.94 (0.23) −2.39 (0.22) −2.40 (0.22) −1.16 (0.21) −1.92 (0.27) −1.99 (0.2)* −2.31 (0.20)* −1.39 (0.20) −2.22 (0.28)* −1.98 (0.21)* −2.26 (0.21)* −1.43 (0.21) −1.62 (0.20) −1.13 (0.19) −0.37 (0.26) −0.16 (0.19)
  Worst pain – – −2.53 (0.25) −2.37 (0.25) −1.35 (0.24) – – – – – – – – −1.75 (0.22) −1.25 (0.21) −0.53 (0.28) −0.18 (0.21)
  Least pain – – −1.77 (0.20) −1.76 (0.20) −0.58 (0.20) – – – – – – – – −1.22 (0.19) −0.73 (0.18) −0.12 (0.26) 0.21 (0.19)
CGi-S −0.72 (0.12) −0.39 (0.12) −0.84 (0.10) −0.84 (0.10) −0.44 (0.10) −0.96 (0.12) −1.06 (0.10)* −1.10 (0.09)* 0.70 (0.10) −0.97 (0.13)* −1.07 (0.10)* −1.14 (0.10)* −0.66 (0.10 −0.57 (0.09) −0.28 (0.08) −0.23 (0.11) −0.04 (0.08)
PGi-i 3.02 (0.17) 3.53 (0.17) 3.11 (1.77) 3.06 (1.73) 3.71 (1.5) 2.85 (0.17)* 3.04 (−0.13)* 2.89 (0.13)* 3.39 (0.13) 2.79 (0.17)* 3.08 (0.13) 2.93 (0.13)* 3.37 (0.13) 3.43 (0.13) 3.72 (0.12) 2.19 (0.15) 2.65 (0.11)*
Notes: *Results were statistically significant (P , 0.05) versus placebo.
Abbreviations: Se, standard error; DLX, duloxetine; PBO, placebo; FiQ, Fibromyalgia impact Questionnaire; CGi-i, Clinical Global impressions of Severity; PGi-i, 
Patient’s Global impressions of improvement.
to those used in the Goldstein et al study. A response was 
defined as a 30% reduction from baseline in the primary 
outcome measure.
All outcome measures, both primary and secondary, 
showed statistically significant improvements versus pla-
cebo for the duloxetine 120 mg group, with exception of 
mean change from baseline in HAM-D score and Dynamic 
Allodynia Severity score. The duloxetine 60 mg group also 
showed significant improvements over placebo with regard 
to most of the outcome measures with the exceptions of the 
HAM-D score, Dynamic Allodynia Severity score, and the 
BPI scores for mood and relationships. For the primary out-
come measure, mean change from baseline for the duloxetine 
60 mg group was −2.50 ± 0.18, for the duloxetine 120 mg 
group was −2.47 ± 0.18, and for the placebo was −1.60 ± 0.18. 
Response rates were superior to placebo for active treatments, 
ie, 68.14% for duloxetine 60 mg, 64.04% for duloxetine 
60 mg, and 43.36% for placebo (P , 0.05). A path analysis 
resulted in a similar outcome to that of the Goldstein study 
in that the effect of duloxetine on pain reduction was due to 
a 98.0% direct effect for the duloxetine 120 mg group and 
92.7% for the duloxetine 60 mg group.
The third study which examined the efficacy of duloxetine 
in treating diabetic neuropathic pain was reported by Wernicke 
et al.38 This was a 12-week study with a similar study design to 
the Raskin et al study, ie, subjects were randomly assigned to 
either placebo, duloxetine 60 mg daily, or duloxetine 120 mg 
daily (given as twice-daily doses of 60 mg). As in the previous 
studies, the primary outcome measure was the reduction in 
the weekly mean 24-hour pain scores. A response was again 
defined as a decrease of 30% from baseline to endpoint in the 
24-hour average pain score. Secondary outcome measures 
were similar to those in the previous two studies. A total of 
334 subjects were randomized to receive treatment, with 108 
receiving placebo, 114 receiving duloxetine 60 mg daily, and 
112 receiving duloxetine 60 mg twice daily. Enrolled patients 
had suffered from diabetes for a mean of 10.2 years, and their 
average age was 60.7 years.
The primary outcome measure for both active treatments 
demonstrated significant improvement versus placebo, with 
the mean change from baseline to week 12 for the 24-hour 
average pain score being −2.84 ± 0.23 for duloxetine 
120 mg daily, −2.72 ± 0.22 for duloxetine 60 mg daily, 
and −1.39 ± 0.23 for placebo. Secondary outcome measures 
that demonstrated significant improvements versus placebo 
for both active treatment groups included BPI pain sever-
ity scores for average pain, worst pain, least pain, and pain 
right now, CGI-S scores, PGI-I scores, and the Short Form 
of the McGill Pain Questionnaire scores. In addition, there 
was a significant improvement in HAMD-17 score for the 
duloxetine 120 mg daily group, but not for the duloxetine 
60 mg daily group. The secondary endpoint of change in 
Dynamic Allodynia Severity score from baseline to endpoint 
showed no statistical difference versus placebo for either of 
the active treatments. The above studies are summarized 
in Table 3.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Safety and tolerability
In general, duloxetine was safe and well tolerated, with 
adverse events being mild to moderate in severity. The 
most common adverse event was nausea (experienced by 
about 30%–45% of duloxetine patients) and was the most 
frequent reason for study discontinuation due to an adverse 
event. Other adverse events that occurred more often than 
placebo were constipation, dry mouth, somnolence, sweat-
ing, changes in appetite, insomnia, and dizziness, although 
these were regarded as mild and occurred at a relatively low 
rate.31–34,38
Serious adverse events occurred at a relatively low fre-
quency, and consisted of appendicitis, and a blood creatine 
phosphokinase and hepatic enzyme increase,32 arthralgia, 
gait disturbance, pseudomonal lung infection, muscular 
weakness, paresthesias, and pseudoneurologic symptoms,33 
asthma and suicidal ideation,34,35 atrial fibrillation, cholecys-
titis, diabetes, nephrolithiasis, urinary calculi, and ventricular 
extrasystoles,37 congestive cardiac failure, coronary artery 
stenosis, and electrolyte embalances,38 chest pain, hypergly-
cemia, and myocardial infarction.36 There was no significant 
difference in serious adverse events between the active and 
placebo groups. There was one fatality, although this was 
determined to be unrelated to the study drug.36 Discontinua-
tion-emergent adverse events occurred at a rate of 1% to 3%, 
and included dizziness, vomiting, crying, nausea, and vertigo, 
with vomiting being the most prominent (3.5%).35
There were differences in rates of discontinuation 
between groups with regard to dose of duloxetine, with the 
higher doses typically having higher rates of discontinuation. 
For example, in the Goldstein et al study,36 discontinuation 
rates were 4.3% for the duloxetine 20 mg group, 13.2% for 
the 60 mg group, and 19.5% for the 120 mg group. In the 
Chappell33 study, 7.45 of patients randomized to duloxetine 
withdrew due to lack of efficacy versus 14.9% of placebo 
patients (P = 0.036).
Discussion
Duloxetine is approved for the treatment for fibromyalgia and 
diabetic peripheral neuropathic pain at doses of 60 mg daily.20 
Several controlled studies have indicated that duloxetine can 
reduce pain symptoms in patients diagnosed with fibromy-
algia or neuropathic pain. Duloxetine demonstrated signifi-
cant reductions in FIQ and BPI scores and other measures 
of pain in fibromyalgia patients, and reductions in 24-hour 
average pain severity score in diabetic neuropathy patients. 
Duloxetine also appears to be relatively well tolerated, with 
adverse events being relatively mild and comparable with Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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other reuptake inhibitors. Interestingly, when a path analysis 
(a statistical analysis that determines the degree of depen-
dency between variables) was conducted, it was found that 
improvements in pain symptoms were due to a direct effect 
of the duloxetine, rather than an indirect effect caused by 
improvements in comorbid conditions, such as depression, for 
example. This analysis is further reinforced by the relatively 
small improvements seen in depressive symptoms in many 
of the studies when compared with placebo.
In general, tolerability seems to be dose-dependent, there-
fore, the recommended dose of duloxetine in the treatment 
for chronic pain due to fibromyalgia and peripheral neu-
ropathy is 60 mg once daily. This daily dose also represents 
the lowest consistently effective dose. Some patients may 
have additional benefit from doses up to 60 mg twice daily, 
although tolerability may be an issue. The adverse effects 
most frequently seen with the use of duloxetine treatment 
include nausea, dizziness, headache, and constipation, and 
may occur more frequently with higher doses. A dose titra-
tion is recommended to increase tolerability and decrease 
initial adverse events. More information on the safety and 
tolerability of duloxetine in the treatment of pain can be found 
elsewhere.39 Drug interactions with duloxetine are minimal 
due to only a weak inhibition of CYP450 2D6, although 
predictable effects mediated by 5-HT remain, and therefore 
caution should be used when other serotonergic medications 
are being used concomitantly, especially monoamine oxidase 
inhibitors. Prescribing precautions for patients taking dulox-
etine include monitoring of hepatotoxicity due to increased 
risk of serum transaminases. For this reason, caution is 
advised in patients with a strong history of alcohol use due 
to potential for combined liver injury.40
There have been no controlled noninferiority compara-
tor studies done with duloxetine, therefore it is difficult to 
assess whether duloxetine is a more appropriate treatment 
option compared with more established and less costly 
alternatives. Other treatment options available for treating 
chronic pain due to fibromyalgia or diabetic neuropathy 
involve the use of many different classes of pharmaco-
logic agents, including tricyclic antidepressants, selective 
serotonin reuptake inhibitors and norepinephrine reuptake 
inhibitors, anticonvulsants, and opiates.39 Anticonvulsants, 
such as gabapentin and pregabalin, are effective at reduc-
ing pain, making them reasonable first-line options for the 
patient suffering from chronic neuropathic pain. Opioid use 
in treating fibromyalgia is controversial, with the current 
evidence for their use being inconclusive.10,41 In addition, 
opiates have a high potential for adverse effects and there 
is always the risk of tolerance and abuse. Antidepressants, 
such as the selective serotonin reuptake inhibitor, fluoxetine, 
have been shown to be modestly effective in treating chronic 
pain associated with fibromyalgia. However, tricyclic anti-
depressants and norepinephrine reuptake inhibitors, such 
as duloxetine and milnacipran (a norepinephrine reuptake 
inhibitor indicated only for the treatment of fibromyalgia 
by the FDA) seem to have better clinical utility. Their 
efficacy in pain reduction is also believed to be associated 
with a direct effect of the drug rather than the drug’s ability 
to reduce depressive or anxiety symptoms.41 Duloxetine is 
one additional option available from the medications in the 
antidepressant class. It should also be noted, that there are 
no direct comparator studies between these different drug 
classes, thus it is difficult to ascertain the superiority of one 
treatment over another.
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